Skip to main content
. 2018 Sep 8;7(18):e009885. doi: 10.1161/JAHA.118.009885

Figure 3.

Figure 3

Temporal trends of 30‐day major adverse cardiovascular events (MACE) and 1‐year mortality according to the Thrombolysis in Myocardial Infarction (TIMI) risk score for secondary prevention among all patients (A), patients with ST‐segment–elevation myocardial infarction (STEMI) (B), and patients with non‐STEMI acute coronary syndrome (NSTE‐ACS) (C).